Nuvation Bio Inc. (NUVB)
NYSE: NUVB · Real-Time Price · USD
6.55
+0.09 (1.39%)
At close: Jan 13, 2026, 4:00 PM EST
6.55
0.00 (0.00%)
After-hours: Jan 13, 2026, 5:05 PM EST
Nuvation Bio Stock Forecast
Stock Price Forecast
The 9 analysts that cover Nuvation Bio stock have a consensus rating of "Strong Buy" and an average price target of $10.44, which forecasts a 59.39% increase in the stock price over the next year. The lowest target is $6.00 and the highest is $17.
Price Target: $10.44 (+59.39%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Nuvation Bio stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 3 | 5 | 5 | 5 |
| Buy | 4 | 4 | 4 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 7 | 7 | 8 | 8 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $18 → $17 | Strong Buy | Maintains | $18 → $17 | +159.54% | Jan 12, 2026 |
| UBS | UBS | Hold Initiates $10 | Hold | Initiates | $10 | +52.67% | Jan 7, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $10 → $18 | Strong Buy | Maintains | $10 → $18 | +174.81% | Dec 11, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +52.67% | Dec 1, 2025 |
| Truist Securities | Truist Securities | Strong Buy Initiates $11 | Strong Buy | Initiates | $11 | +67.94% | Nov 24, 2025 |
Financial Forecast
Revenue This Year
55.86M
from 7.87M
Increased by 609.55%
Revenue Next Year
166.42M
from 55.86M
Increased by 197.91%
EPS This Year
-0.60
from -2.11
EPS Next Year
-0.52
from -0.60
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 74.3M | 218.1M | ||||
| Avg | 55.9M | 166.4M | ||||
| Low | 34.7M | 104.3M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 844.2% | 290.4% | ||||
| Avg | 609.6% | 197.9% | ||||
| Low | 340.7% | 86.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | -0.60 | -0.41 | ||
| Avg | -0.60 | -0.52 | ||
| Low | -0.63 | -1.05 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | - | - | ||
| Avg | - | - | ||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.